Tumour homing and therapeutic effect of colloidal nanoparticles depend on the number of attached antibodies

Miriam Colombo, Luisa Fiandra, Giulia Alessio, Serena Mazzucchelli, Manuela Nebuloni, Clara De Palma, Karsten Kantner, Beatriz Pelaz, Rany Rotem, Fabio Ruggero Corsi, Wolfgang J. Parak, Davide Prosperi

Research output: Contribution to journalArticle

Abstract

Active targeting of nanoparticles to tumours can be achieved by conjugation with specific antibodies. Specific active targeting of the HER2 receptor is demonstrated in vitro and in vivo with a subcutaneous MCF-7 breast cancer mouse model with trastuzumab-functionalized gold nanoparticles. The number of attached antibodies per nanoparticle was precisely controlled in a way that each nanoparticle was conjugated with either exactly one or exactly two antibodies. As expected, in vitro we found a moderate increase in targeting efficiency of nanoparticles with two instead of just one antibody attached per nanoparticle. However, the in vivo data demonstrate that best effect is obtained for nanoparticles with only exactly one antibody. There is indication that this is based on a size-related effect. These results highlight the importance of precisely controlling the ligand density on the nanoparticle surface for optimizing active targeting, and that less antibodies can exhibit more effect.

Original languageEnglish
Pages (from-to)13818
JournalNature Communications
Volume7
DOIs
Publication statusPublished - Dec 19 2016

Fingerprint

homing
Therapeutic Uses
antibodies
Nanoparticles
Tumors
tumors
nanoparticles
Antibodies
Neoplasms
conjugation
breast
Gold
mice
indication
cancer
gold
Breast Neoplasms
Ligands
ligands

Keywords

  • Journal Article

Cite this

Colombo, M., Fiandra, L., Alessio, G., Mazzucchelli, S., Nebuloni, M., De Palma, C., ... Prosperi, D. (2016). Tumour homing and therapeutic effect of colloidal nanoparticles depend on the number of attached antibodies. Nature Communications, 7, 13818. https://doi.org/10.1038/ncomms13818

Tumour homing and therapeutic effect of colloidal nanoparticles depend on the number of attached antibodies. / Colombo, Miriam; Fiandra, Luisa; Alessio, Giulia; Mazzucchelli, Serena; Nebuloni, Manuela; De Palma, Clara; Kantner, Karsten; Pelaz, Beatriz; Rotem, Rany; Corsi, Fabio Ruggero; Parak, Wolfgang J.; Prosperi, Davide.

In: Nature Communications, Vol. 7, 19.12.2016, p. 13818.

Research output: Contribution to journalArticle

Colombo, M, Fiandra, L, Alessio, G, Mazzucchelli, S, Nebuloni, M, De Palma, C, Kantner, K, Pelaz, B, Rotem, R, Corsi, FR, Parak, WJ & Prosperi, D 2016, 'Tumour homing and therapeutic effect of colloidal nanoparticles depend on the number of attached antibodies', Nature Communications, vol. 7, pp. 13818. https://doi.org/10.1038/ncomms13818
Colombo, Miriam ; Fiandra, Luisa ; Alessio, Giulia ; Mazzucchelli, Serena ; Nebuloni, Manuela ; De Palma, Clara ; Kantner, Karsten ; Pelaz, Beatriz ; Rotem, Rany ; Corsi, Fabio Ruggero ; Parak, Wolfgang J. ; Prosperi, Davide. / Tumour homing and therapeutic effect of colloidal nanoparticles depend on the number of attached antibodies. In: Nature Communications. 2016 ; Vol. 7. pp. 13818.
@article{ac6f972e9aaf44cd99b45f4426975ffd,
title = "Tumour homing and therapeutic effect of colloidal nanoparticles depend on the number of attached antibodies",
abstract = "Active targeting of nanoparticles to tumours can be achieved by conjugation with specific antibodies. Specific active targeting of the HER2 receptor is demonstrated in vitro and in vivo with a subcutaneous MCF-7 breast cancer mouse model with trastuzumab-functionalized gold nanoparticles. The number of attached antibodies per nanoparticle was precisely controlled in a way that each nanoparticle was conjugated with either exactly one or exactly two antibodies. As expected, in vitro we found a moderate increase in targeting efficiency of nanoparticles with two instead of just one antibody attached per nanoparticle. However, the in vivo data demonstrate that best effect is obtained for nanoparticles with only exactly one antibody. There is indication that this is based on a size-related effect. These results highlight the importance of precisely controlling the ligand density on the nanoparticle surface for optimizing active targeting, and that less antibodies can exhibit more effect.",
keywords = "Journal Article",
author = "Miriam Colombo and Luisa Fiandra and Giulia Alessio and Serena Mazzucchelli and Manuela Nebuloni and {De Palma}, Clara and Karsten Kantner and Beatriz Pelaz and Rany Rotem and Corsi, {Fabio Ruggero} and Parak, {Wolfgang J.} and Davide Prosperi",
year = "2016",
month = "12",
day = "19",
doi = "10.1038/ncomms13818",
language = "English",
volume = "7",
pages = "13818",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "NLM (Medline)",

}

TY - JOUR

T1 - Tumour homing and therapeutic effect of colloidal nanoparticles depend on the number of attached antibodies

AU - Colombo, Miriam

AU - Fiandra, Luisa

AU - Alessio, Giulia

AU - Mazzucchelli, Serena

AU - Nebuloni, Manuela

AU - De Palma, Clara

AU - Kantner, Karsten

AU - Pelaz, Beatriz

AU - Rotem, Rany

AU - Corsi, Fabio Ruggero

AU - Parak, Wolfgang J.

AU - Prosperi, Davide

PY - 2016/12/19

Y1 - 2016/12/19

N2 - Active targeting of nanoparticles to tumours can be achieved by conjugation with specific antibodies. Specific active targeting of the HER2 receptor is demonstrated in vitro and in vivo with a subcutaneous MCF-7 breast cancer mouse model with trastuzumab-functionalized gold nanoparticles. The number of attached antibodies per nanoparticle was precisely controlled in a way that each nanoparticle was conjugated with either exactly one or exactly two antibodies. As expected, in vitro we found a moderate increase in targeting efficiency of nanoparticles with two instead of just one antibody attached per nanoparticle. However, the in vivo data demonstrate that best effect is obtained for nanoparticles with only exactly one antibody. There is indication that this is based on a size-related effect. These results highlight the importance of precisely controlling the ligand density on the nanoparticle surface for optimizing active targeting, and that less antibodies can exhibit more effect.

AB - Active targeting of nanoparticles to tumours can be achieved by conjugation with specific antibodies. Specific active targeting of the HER2 receptor is demonstrated in vitro and in vivo with a subcutaneous MCF-7 breast cancer mouse model with trastuzumab-functionalized gold nanoparticles. The number of attached antibodies per nanoparticle was precisely controlled in a way that each nanoparticle was conjugated with either exactly one or exactly two antibodies. As expected, in vitro we found a moderate increase in targeting efficiency of nanoparticles with two instead of just one antibody attached per nanoparticle. However, the in vivo data demonstrate that best effect is obtained for nanoparticles with only exactly one antibody. There is indication that this is based on a size-related effect. These results highlight the importance of precisely controlling the ligand density on the nanoparticle surface for optimizing active targeting, and that less antibodies can exhibit more effect.

KW - Journal Article

U2 - 10.1038/ncomms13818

DO - 10.1038/ncomms13818

M3 - Article

C2 - 27991503

VL - 7

SP - 13818

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

ER -